# US 2022/0031835 A1 · Nanoparticle vaccines with novel structural components

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031835 A1
- Document ID: US20220031835A1
- Status: Published application
- Kind: A1
- Application number: 17/386,289
- Filed: 2021-07-27
- Published: 2022-02-03
- Earliest claimed: 2018-06-13
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: Linling He; Jiang Zhu
- Web page: https://patentgrep.com/patent/US20220031835A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 39/12: Viral antigens
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 33/06: Antimalarials
- C12N 15/86: Viral vectors
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- B82Y 40/00: Manufacture or treatment of nanostructures
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16111: concerning HIV env
- C12N 2760/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/14134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.

## Claims

### Claim 1

A polynucleotide, encoding a fusion protein comprising (a) an polypeptide immunogen, (b) a self-assembling nanoparticle subunit, and (c) a locking domain subunit that comprises the amino acid sequence selected from SEQ ID NOs:1-9, or a conservatively modified variant thereof.

### Claim 2 (depends on 1)

The polynucleotide of claim 1, wherein the polypeptide immunogen is located at the N-terminus of the fusion protein.

### Claim 3 (depends on 1)

The polynucleotide of claim 1, wherein N-terminus of the locking domain subunit is fused to C-terminus of the self-assembling nanoparticle subunit via a linker sequence.

### Claim 4 (depends on 1)

The polynucleotide of claim 1, wherein the fusion protein further comprises a pan-reactive T-cell epitope.

### Claim 5 (depends on 4)

The polynucleotide of claim 4, wherein N-terminus of the pan-reactive T-cell epitope is fused to the C-terminus of the locking domain subunit.

### Claim 6 (depends on 1)

The polynucleotide of claim 1, wherein the fusion protein further comprises a neck region inserted between the immunogen and the self-assembling nanoparticle subunit, wherein the neck region comprises a 3-helix protein domain that elevates the immunogen further away from the surface of the self-assembling nanoparticle.

### Claim 7 (depends on 1)

The polynucleotide of claim 1, wherein the fusion protein further comprises a protein domain inserted between the polypeptide immunogen and the self-assembling nanoparticle subunit, wherein the protein domain stabilizes the polypeptide immunogen.

### Claim 8 (depends on 1)

The polynucleotide of claim 1, wherein the self-assembling nanoparticle is a ball-shaped nanoparticle with rotational symmetry.

### Claim 9 (depends on 8)

The polynucleotide of claim 8, wherein the rotational symmetry has 3-fold axis and/or 5-fold axis.

### Claim 10 (depends on 9)

The polynucleotide of claim 9, wherein the nanoparticle is of an icosahedral structure.

### Claim 11 (depends on 1)

The polynucleotide of claim 1, wherein the polypeptide immunogen is a viral immunogen.

### Claim 12 (depends on 11)

The polynucleotide of claim 11, wherein the polypeptide immunogen is a viral immunogen from a virus utilizing class-I fusion mechanism.

### Claim 13 (depends on 12)

The polynucleotide of claim 12, wherein the virus is selected from the group consisting of HIV-1 virus, Ebola virus, Marburg virus, Arenaviruses, respiratory syncytial viruses (RSV), and coronaviruses.

### Claim 14 (depends on 11)

The polynucleotide of claim 11, wherein the polypeptide immunogen is a viral immunogen from a virus utilizing class-II fusion mechanism.

### Claim 15 (depends on 14)

The polynucleotide of claim 14, wherein the virus utilizing class-II fusion mechanism is HCV or Zika virus.

### Claim 16 (depends on 1)

The polynucleotide of claim 1, wherein the polypeptide immunogen is a non-viral immunogen.

### Claim 17 (depends on 16)

The polynucleotide of claim 16, wherein the polypeptide immunogen is an antigen from Plasmodium falciparum, an antigen from Mycobacterium tuberculosis (TB), or human protein proprotein convertase subtilisin/kexin type 9 (PCSK9).

### Claim 18 (depends on 1)

The polynucleotide of claim 1, wherein the polypeptide immunogen is an HIV-1 Env trimer protein.

### Claim 19 (depends on 18)

The polynucleotide of claim 18, wherein N-terminus of the locking domain subunit is fused to C-terminus of the nanoparticle subunit via a linker sequence that comprises one or more tandem copies of GGGGS (SEQ ID NO:17).

### Claim 20 (depends on 18)

The polynucleotide of claim 18, wherein the fusion protein further comprises a pan-reactive T-cell epitope.

### Claim 21 (depends on 20)

The polynucleotide of claim 20, wherein N-terminus of the pan-reactive T-cell epitope is fused to the C-terminus of the locking domain subunit.

### Claim 22 (depends on 20)

The polynucleotide of claim 20, wherein the pan-reactive T-cell epitope comprises the sequence AKFVAAWTLKAAA (SEQ ID NO:18).

### Claim 23 (depends on 18)

The polynucleotide of claim 18, wherein C-terminus of subunit of the HIV-1 trimer protein is covalently linked to N-terminus of subunit of the self-assembling nanoparticle.

### Claim 24 (depends on 18)

The polynucleotide of claim 18, wherein the HIV-1 trimer protein subunit is fused to the self-assembling nanoparticle subunit via a linker sequence.

### Claim 25 (depends on 24)

The polynucleotide of claim 24, wherein the linker sequence comprises the sequence (GaSb)n, wherein a is an integer of 1 to 5, b is an integer of 1 to 2, and n is an integer of 1 to 5.

### Claim 26 (depends on 18)

The polynucleotide of claim 18, wherein the self-assembling nanoparticle comprises a trimeric sequence.

### Claim 27 (depends on 18)

The polynucleotide of claim 18, wherein the subunit of the self-assembling nanoparticle comprises the polypeptide selected from SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:25 or SEQ ID NO:26, or a conservatively modified variant thereof.

### Claim 28 (depends on 18)

The polynucleotide of claim 18, wherein the HIV-1 Env trimer protein is a gp140 trimer.

### Claim 29 (depends on 18)

The polynucleotide of claim 18, wherein the HIV-1 Env trimer protein is an uncleaved prefusion-optimized (UFO) gp140 trimer.

### Claim 30 (depends on 29)

The polynucleotide of claim 29, wherein the UFO gp140 trimer is a chimeric trimer comprising a modified gp41ECTO domain from HIV-1 strain BG505.

### Claim 31 (depends on 29)

The polynucleotide of claim 29, wherein subunit of the UFO gp140 trimer comprises the sequence SEQ ID NO:23, or a conservatively modified variant thereof.

### Claim 32 (depends on 29)

The polynucleotide of claim 29, wherein the fusion protein comprises from the N-terminus to the C-terminus: HIV-1 uncleaved prefusion-optimized (UFO) gp140 trimer subunit comprising SEQ ID NO:23, self-assembling nanoparticle subunit comprising SEQ ID NO:21 (E2p), the locking domain subunit comprising SEQ ID NO:1 (LD4), and T-cell epitope AKFVAAWTLKAAA (SEQ ID NO:18).

### Claim 33 (depends on 32)

The polynucleotide of claim 32, wherein the fusion protein further comprises a first linker sequence (GGGGS)2 (SEQ ID NO:24) between the HIV-1 uncleaved prefusion-optimized (UFO) gp140 trimer subunit and the self-assembling nanoparticle subunit, and/or a second linker sequence GGGGS (SEQ ID NO:17) between the self-assembling nanoparticle subunit and the locking domain subunit.

### Claim 34 (depends on 29)

The polynucleotide of claim 29, wherein the fusion protein comprises from the N-terminus to the C-terminus: HIV-1 uncleaved prefusion-optimized (UFO) gp140 trimer comprising SEQ ID NO:23, self-assembling nanoparticle subunit comprising SEQ ID NO:22 or 25 (I3-01), the locking domain subunit comprising SEQ ID NO:2 (LD7), and T-cell epitope AKFVAAWTLKAAA (SEQ ID NO:18).

### Claim 35 (depends on 34)

The polynucleotide of claim 34, wherein the fusion protein further comprises a first linker sequence (GGGGS)2 (SEQ ID NO:24) between the HIV-1 uncleaved prefusion-optimized (UFO) gp140 trimer subunit and the self-assembling nanoparticle subunit, and/or a second linker sequence GGGGS (SEQ ID NO:17) between the self-assembling nanoparticle subunit and the locking domain subunit.

### Claim 36 (depends on 1)

A vector comprising the polynucleotide of claim 1.

### Claim 37 (depends on 1)

A pharmaceutical composition, comprising the polynucleotide of claim 1, and a pharmaceutically acceptable carrier.
